View in EDS

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Saved in:
Bibliographic Details
Title: Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
Authors: Yong K; aDepartment of Haematology, Cancer Institute, University College London, London, UK., Martin T; bDepartment of Hematology, University of California at San Francisco, San Francisco, CA, USA., Dimopoulos MA; cThe National and Kapodistrian University of Athens, Athens, Greece., Mikhael J; dTranslational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Capra M; eCentro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil., Facon T; fDepartment of Haematology, Lille University Hospital, Lille, France., Hajek R; gDepartment of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Špička I; hDepartment of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Baker R; iPerth Blood Institute, Murdoch University, Perth, Australia., Kim K; jDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Martinez G; kHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Min CK; lDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Pour L; mDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Leleu X; nService d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France., Oriol A; oInstitut Josep Carreras and Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain., Koh Y; pDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea., Suzuki K; qMyeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan., Casca F; rIvidata Life Science, Levallois-Perret, France., Macé S; sSanofi, R&D, Chilly-Mazarin, France., Moreau P; tDepartment of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Source: Future oncology (London, England) [Future Oncol] 2026 Jun 27, pp. 1-13. Date of Electronic Publication: 2026 Jun 27.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42363804
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yong+K%22">Yong K</searchLink>; aDepartment of Haematology, Cancer Institute, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Martin+T%22">Martin T</searchLink>; bDepartment of Hematology, University of California at San Francisco, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; cThe National and Kapodistrian University of Athens, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Mikhael+J%22">Mikhael J</searchLink>; dTranslational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.<br /><searchLink fieldCode="AU" term="%22Capra+M%22">Capra M</searchLink>; eCentro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Facon+T%22">Facon T</searchLink>; fDepartment of Haematology, Lille University Hospital, Lille, France.<br /><searchLink fieldCode="AU" term="%22Hajek+R%22">Hajek R</searchLink>; gDepartment of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Špička+I%22">Špička I</searchLink>; hDepartment of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Baker+R%22">Baker R</searchLink>; iPerth Blood Institute, Murdoch University, Perth, Australia.<br /><searchLink fieldCode="AU" term="%22Kim+K%22">Kim K</searchLink>; jDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Martinez+G%22">Martinez G</searchLink>; kHospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Min+CK%22">Min CK</searchLink>; lDepartment of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Pour+L%22">Pour L</searchLink>; mDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; nService d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France.<br /><searchLink fieldCode="AU" term="%22Oriol+A%22">Oriol A</searchLink>; oInstitut Josep Carreras and Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain.<br /><searchLink fieldCode="AU" term="%22Koh+Y%22">Koh Y</searchLink>; pDepartment of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Suzuki+K%22">Suzuki K</searchLink>; qMyeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Casca+F%22">Casca F</searchLink>; rIvidata Life Science, Levallois-Perret, France.<br /><searchLink fieldCode="AU" term="%22Macé+S%22">Macé S</searchLink>; sSanofi, R&D, Chilly-Mazarin, France.<br /><searchLink fieldCode="AU" term="%22Moreau+P%22">Moreau P</searchLink>; tDepartment of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2026 Jun 27, pp. 1-13. <i>Date of Electronic Publication: </i>2026 Jun 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42363804
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14796694.2026.2683336
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1
    Titles:
      – TitleFull: Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yong K
      – PersonEntity:
          Name:
            NameFull: Martin T
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Mikhael J
      – PersonEntity:
          Name:
            NameFull: Capra M
      – PersonEntity:
          Name:
            NameFull: Facon T
      – PersonEntity:
          Name:
            NameFull: Hajek R
      – PersonEntity:
          Name:
            NameFull: Špička I
      – PersonEntity:
          Name:
            NameFull: Baker R
      – PersonEntity:
          Name:
            NameFull: Kim K
      – PersonEntity:
          Name:
            NameFull: Martinez G
      – PersonEntity:
          Name:
            NameFull: Min CK
      – PersonEntity:
          Name:
            NameFull: Pour L
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Oriol A
      – PersonEntity:
          Name:
            NameFull: Koh Y
      – PersonEntity:
          Name:
            NameFull: Suzuki K
      – PersonEntity:
          Name:
            NameFull: Casca F
      – PersonEntity:
          Name:
            NameFull: Macé S
      – PersonEntity:
          Name:
            NameFull: Moreau P
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 06
              Text: 2026 Jun 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1